News | June 28, 2022
PHARMAP 2022 concludes with productive networking of pharma leaders
The Congress was held on June, 20-21, 2022 in Berlin, Germany
The Congress was held on June, 20-21, 2022 in Berlin, Germany
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Silo enters into commercial evaluation license agreement for next generation liposomes
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Subscribe To Our Newsletter & Stay Updated
